{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:46:33Z","timestamp":1777376793585,"version":"3.51.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To test the ability of a multicriteria decision analysis (MCDA) model to incorporate disparate data sources of varying quality along with clinical judgement in a benefit\u2013risk assessment of six well-known pain-relief drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Six over-the-counter (OTC) analgesics were evaluated against three favourable effects and eight unfavourable effects by seven experts who specialise in the relief of pain, two in a 2-day facilitated workshop whose input data and judgements were later peer-reviewed by five additional experts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Ibuprofen salts and solubilised emerged with the best benefit\u2013risk profile, followed by naproxen, ibuprofen acid, diclofenac, paracetamol and aspirin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Multicriteria decision analysis enabled participants to evaluate the OTC analgesics against a range of favourable and unfavourable effects in a group setting that enabled all issues to be openly aired and debated. The model was easily communicated and understood by the peer reviewers, so the model should be comprehensible to physicians, pharmacists and other health professionals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12770","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T12:24:38Z","timestamp":1499948678000},"page":"1364-1373","source":"Crossref","is-referenced-by-count":20,"title":["Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics"],"prefix":"10.1093","volume":"69","author":[{"given":"Andrew","family":"Moore","sequence":"first","affiliation":[{"name":"Pain Research, Nuffield Division of Anaesthetics, University of Oxford , Oxford,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5577-9029","authenticated-orcid":false,"given":"Anne","family":"Crossley","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Consumer Health , Slough,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Ng","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Consumer Health , Slough,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Management, London School of Economics and Political Science , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zg\u00fcr","family":"Sancak","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Consumer Health , Slough,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K D","family":"Rainsford","sequence":"additional","affiliation":[{"name":"Biomedical Research Centre, Sheffield Hallam University , Sheffield,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,1]]},"reference":[{"key":"2024103012571387900_jphp12770-cit-0001","first-page":"215","article-title":"Pharmacology and biochemistry of salicylates and related drugs","volume-title":"Aspirin and Related Drugs","author":"Rainsford","year":"2004"},{"key":"2024103012571387900_jphp12770-cit-0002","doi-asserted-by":"crossref","DOI":"10.1002\/9781118743614","volume-title":"Ibuprofen: Pharmacology, Therapeutics and Side Effects","author":"Rainsford","year":"2015"},{"key":"2024103012571387900_jphp12770-cit-0003","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12889-015-1774-6","article-title":"Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: impact of gender, age, exercise and prescription of opioids","volume":"15","author":"Dale","year":"2015","journal-title":"BMC Public Health"},{"key":"2024103012571387900_jphp12770-cit-0004","volume-title":"Regulation (EU) No 1235\/2010 of the European Parliament and of the Council of the European Union","author":"EMEA","year":"2010"},{"key":"2024103012571387900_jphp12770-cit-0005","volume-title":"PRAC Work Plan 2015 EMA\/PRAC\/794108\/2013","author":"EMA. European Medicines Agency: Procedure Management and Committees Support Division","year":"2015"},{"key":"2024103012571387900_jphp12770-cit-0006","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jcph.22","article-title":"A decision-analysis tool for benefit-risk assessment of nonprescription drugs","volume":"53","author":"Brass","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2024103012571387900_jphp12770-cit-0007","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1002\/pds.1435","article-title":"A quantitative approach to benefit-risk assessment of medicines \u2013 part 1: the development of a new model using multi-criteria decision analysis","volume":"15","author":"Mussen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024103012571387900_jphp12770-cit-0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/bimj.201300248","article-title":"A case study using the PROACT-URL and BRAT frameworks for structured benefit risk assessment","volume":"58","author":"Nixon","year":"2015","journal-title":"Biom J"},{"key":"2024103012571387900_jphp12770-cit-0009","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.ddtec.2011.03.001","article-title":"Is quantitative benefit-risk modelling of drugs desirable or possible?","volume":"8","author":"Phillips","year":"2011","journal-title":"Drug Discov Today Technol"},{"key":"2024103012571387900_jphp12770-cit-0010","first-page":"59","article-title":"Benefit-risk modeling of medicinal products: methods and applications","volume-title":"Benefit-Risk Assessment in Pharmaceutical Research and Development","author":"Phillips","year":"2014"},{"key":"2024103012571387900_jphp12770-cit-0011","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"2024103012571387900_jphp12770-cit-0012","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000360220","article-title":"Estimating the harms of nicotine-containing products using the MCDA approach","volume":"20","author":"Nutt","year":"2014","journal-title":"Eur Addict Res"},{"issue":"9","key":"2024103012571387900_jphp12770-cit-0013","first-page":"CD008659","article-title":"Single dose oral analgesics for acute postoperative pain in adults","author":"Moore","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2024103012571387900_jphp12770-cit-0014","first-page":"CD010794","article-title":"Non-prescription (OTC) oral analgesics for acute pain \u2013 an overview of Cochrane reviews","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012571387900_jphp12770-cit-0015","volume-title":"HiView3 Software","author":"Catalyze","year":"2017"},{"key":"2024103012571387900_jphp12770-cit-0016","volume-title":"Multi-Criteria Analysis: A Manual","author":"Dodgson","year":"2000"},{"key":"2024103012571387900_jphp12770-cit-0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pain.2013.08.013","article-title":"Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain","volume":"155","author":"Moore","year":"2014","journal-title":"Pain"},{"key":"2024103012571387900_jphp12770-cit-0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2036.2012.05030.x","article-title":"Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules","volume":"35","author":"Hawkey","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103012571387900_jphp12770-cit-0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-0348-0496-7","volume-title":"Ibuprofen: Pharmacology, Therapeutics and Side Effects","author":"Rainsford","year":"2012"},{"issue":"7","key":"2024103012571387900_jphp12770-cit-0020","first-page":"CD004768","article-title":"Single dose oral diclofenac for acute postoperative pain in adults","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012571387900_jphp12770-cit-0021","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1037\/0033-2909.84.1.158","article-title":"Quality of group judgment","volume":"84","author":"Einhorn","year":"1977","journal-title":"Psychol Bull"},{"issue":"6","key":"2024103012571387900_jphp12770-cit-0022","first-page":"CD011889","article-title":"Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults","author":"Stephens","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012571387900_jphp12770-cit-0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ijcp.12655","article-title":"Analgesic safety \u2013 myths, mysteries and misconceptions","volume":"182","author":"Moore","year":"2015","journal-title":"Int J Clin Pract Suppl"},{"key":"2024103012571387900_jphp12770-cit-0024","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(15)01170-8","article-title":"Does paracetamol still have a future in osteoarthritis?","volume":"387","author":"Moore","year":"2016","journal-title":"Lancet"},{"key":"2024103012571387900_jphp12770-cit-0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/ejhpharm-2016-000952","article-title":"Paracetamol and pain: the kiloton problem","volume":"23","author":"Moore","year":"2016","journal-title":"Eur J Hosp Pharm"},{"key":"2024103012571387900_jphp12770-cit-0026","doi-asserted-by":"crossref","first-page":"h1225","DOI":"10.1136\/bmj.h1225","article-title":"Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials","volume":"350","author":"Machado","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"2024103012571387900_jphp12770-cit-0027","first-page":"CD012230","article-title":"Paracetamol for low back pain","author":"Saragiotto","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012571387900_jphp12770-cit-0028","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(16)30002-2","article-title":"Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis","volume":"387","author":"da Costa","year":"2016","journal-title":"Lancet"},{"key":"2024103012571387900_jphp12770-cit-0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/0022-3859.132370","article-title":"Paracetamol in osteoarthritis: NICE guidelines or not so nice","volume":"60","author":"Kamath","year":"2014","journal-title":"J Postgrad Med"},{"key":"2024103012571387900_jphp12770-cit-0030","doi-asserted-by":"crossref","first-page":"g1545","DOI":"10.1136\/bmj.g1545","article-title":"NICE keeps paracetamol in UK guidelines on osteoarthritis","volume":"348","author":"Wise","year":"2014","journal-title":"BMJ"},{"key":"2024103012571387900_jphp12770-cit-0031","volume-title":"Consumer Updates \u2013 New Steps Aimed at Cutting Risks from Acetaminophen","author":"FDA","year":"2011"},{"key":"2024103012571387900_jphp12770-cit-0032","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Abramson","year":"2013","journal-title":"Lancet"},{"key":"2024103012571387900_jphp12770-cit-0033","doi-asserted-by":"crossref","first-page":"e0126347","DOI":"10.1371\/journal.pone.0126347","article-title":"Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study","volume":"10","author":"Tsai","year":"2015","journal-title":"PLoS One"},{"key":"2024103012571387900_jphp12770-cit-0034","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.sjpain.2016.06.005","article-title":"Assessing the relationship between chronic pain and cardiovascular disease: a systematic review and meta-analysis","volume":"13","author":"Fayaz","year":"2016","journal-title":"Scand J Pain"},{"key":"2024103012571387900_jphp12770-cit-0035","doi-asserted-by":"crossref","first-page":"d1165","DOI":"10.1136\/bmj.d1165","article-title":"All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study","volume":"342","author":"N\u00fcesch","year":"2011","journal-title":"BMJ"},{"key":"2024103012571387900_jphp12770-cit-0036","doi-asserted-by":"crossref","first-page":"i4857","DOI":"10.1136\/bmj.i4857","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study","volume":"354","author":"Arf\u00e8","year":"2016","journal-title":"BMJ"},{"key":"2024103012571387900_jphp12770-cit-0037","doi-asserted-by":"crossref","first-page":"i5163","DOI":"10.1136\/bmj.i5163","article-title":"NSAIDs and the failing heart","volume":"354","author":"Gislason","year":"2016","journal-title":"BMJ"},{"key":"2024103012571387900_jphp12770-cit-0038","volume-title":"Decisions with Multiple Objectives: Preferences and Value Tradeoffs","author":"Keeney","year":"1976"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12770","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/10\/1364\/60231828\/jphp12770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/10\/1364\/60231828\/jphp12770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:30:25Z","timestamp":1730313025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/69\/10\/1364\/6127817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,1]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,1]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12770","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,10,1]]}}}